Predictive value of using plasma long non-coding RNAs ANRIL and HOXA11-AS for in-stent restenosis

Zhijiang Jin1,2, Hongfeng Shen1,2, Wei Cha1,2

  • 1Department of Cardiology, The Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China.

Insights

Plasma levels of long non-coding RNA (lncRNA) ANRIL and HOXA11-AS can help predict in-stent restenosis (ISR) after coronary stent implantation. Elevated ANRIL and reduced HOXA11-AS levels are associated with increased ISR risk.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • In-stent restenosis (ISR) is a significant complication following coronary stent implantation.
  • Predicting ISR risk is crucial for effective prevention strategies.
  • Current predictors for ISR remain limited.

Purpose of the Study:

  • To investigate the association between plasma long non-coding RNA (lncRNA) levels and ISR.
  • To identify potential lncRNA biomarkers for ISR risk stratification.

Main Methods:

  • Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was used to measure plasma lncRNA expression in 410 patients.
  • Patients received drug-eluting stents (DES) and were followed for 12-36 months.
  • Coronary angiography assessed ISR, defined as >50% diameter stenosis.

Main Results:

  • RNA antisense non-coding RNA at the INK4 locus (ANRIL) was upregulated in ISR patients.
  • HOXA11 antisense (HOXA11-AS) was downregulated in ISR patients.
  • Logistic regression identified ANRIL as a risk factor and HOXA11-AS as a protective factor for ISR. ROC analysis showed combined ANRIL and HOXA11-AS levels improved ISR prediction accuracy (auROC=0.844).

Conclusions:

  • Increased plasma ANRIL and decreased HOXA11-AS expression are associated with ISR.
  • Combined detection of ANRIL and HOXA11-AS plasma levels offers superior predictive value for ISR.
  • Multiplex detection of lncRNAs holds promise for future ISR prediction strategies.